Product Description
Mechanisms of Action: Voltage-Gated Sodium Channel Blocker
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Bangladesh | China | Dominican Republic | Egypt | India | Indonesia | Italy | Jordan | Korea | Malaysia | Pakistan | Philippines | Russia | Singapore | Taiwan | United Arab Emirates | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: DKSH
Company Location:
Company CEO:
Additonal Commercial Interests: Eisai
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Low Back Pain|Spasm|Acute Pain|Back Pain|Muscle Cramp|Musculoskeletal Pain
Phase 2: Amyotrophic Lateral Sclerosis|Acute Pain|Low Back Pain
Phase 1: Low Back Pain
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| ChiCTR2400083349 | N/A |
Recruiting |
Thoracic Outlet Syndrome |
2025-04-30 |
|
| ChiCTR2300069735 | N/A |
Not yet recruiting |
Pain Unspecified |
2024-03-26 |
|
| ChiCTR-IOR-17012680 | N/A |
Not yet recruiting |
Scoliosis |
2019-12-31 |
|
| NVP-1203 | P1 |
Withdrawn |
Low Back Pain |
2019-12-01 |
|
| NVP-1203 | P1 |
Withdrawn |
Low Back Pain |
2019-12-01 |
|
| NVP-1203 | P1 |
Withdrawn |
Low Back Pain |
2019-12-01 |